Clinical Trial Update: Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating BF2.649 for excessive daytime sleepiness in narcolepsy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Narcolepsy

Drugs mentioned

• BF2.649 (BF2.649)

Snippet

Sponsor: Bioprojet | Conditions: Treatment of Excessive Daytime Sleepiness in Narcolepsy | Phase 3 | Status: COMPLETED